[Systemic sclerosis].

Systemische Sklerose.

Connective tissue hyperplasia Interdisciplinary health team Organ-specific treatment Quality of life Scleroderma

Journal

Dermatologie (Heidelberg, Germany)

ISSN: 2731-7013

Titre abrégé: Dermatologie (Heidelb)

Pays: Germany

ID NLM: 9918384885206676

Informations de publication

Date de publication:
16 Feb 2024

Historique:

accepted: 10 01 2024

medline: 17 2 2024

pubmed: 17 2 2024

entrez: 17 2 2024

Statut: aheadofprint

Résumé

Systemic sclerosis (SSc) is a very heterogeneous, chronic, rare, but socioeconomically important disease with a severe disease course and severe impairment of the quality of life of affected patients. Overview of the current state of research on the pathogenesis, diagnosis and therapy of SSc. A literature search was performed. The pathogenesis of SSc is not fully understood. ACR/EULAR criteria allow the diagnosis of early forms of SSc. Classification into limited cutaneous SSc and diffuse cutaneous SSc is of prognostic and therapeutic relevance. New organ-specific treatment options for SSc have led to improved quality of life and prognosis. HINTERGRUND: Die systemische Sklerose (SSc) stellt eine sehr heterogene, chronische, zwar seltene, jedoch sozioökonomisch bedeutsame Erkrankung mit schwerem Krankheitsverlauf und starker Einschränkung der Lebensqualität betroffener Patienten dar. Es wird eine Übersicht zum aktuellen Forschungsstand zu Pathogenese, Diagnostik und Therapie der SSc gegeben. Es erfolgte eine Literaturrecherche. Die Pathogenese der SSc bleibt bislang weiterhin nicht gänzlich geklärt. ACR(American College of Rheumatology)/EULAR(European League Against Rheumatism)-Kriterien erlauben eine Diagnose auch früher SSc-Formen. Die Klassifikation in limitierte kutane systemische Sklerose (lcSSc) und diffuse kutane systemische Sklerose (dcSSc) ist von prognostischer und therapeutischer Relevanz. Neue organspezifische Therapiemöglichkeiten der SSc haben zu einer verbesserten Lebensqualität und Prognose geführt.

Sections du résumé

BACKGROUND BACKGROUND

OBJECTIVES OBJECTIVE

Overview of the current state of research on the pathogenesis, diagnosis and therapy of SSc.

METHODS METHODS

A literature search was performed.

RESULTS RESULTS

The pathogenesis of SSc is not fully understood. ACR/EULAR criteria allow the diagnosis of early forms of SSc. Classification into limited cutaneous SSc and diffuse cutaneous SSc is of prognostic and therapeutic relevance. New organ-specific treatment options for SSc have led to improved quality of life and prognosis.

ZUSAMMENFASSUNG UNASSIGNED

HINTERGRUND: Die systemische Sklerose (SSc) stellt eine sehr heterogene, chronische, zwar seltene, jedoch sozioökonomisch bedeutsame Erkrankung mit schwerem Krankheitsverlauf und starker Einschränkung der Lebensqualität betroffener Patienten dar.

FRAGESTELLUNG UNASSIGNED

Es wird eine Übersicht zum aktuellen Forschungsstand zu Pathogenese, Diagnostik und Therapie der SSc gegeben.

MATERIAL UND METHODE UNASSIGNED

Es erfolgte eine Literaturrecherche.

ERGEBNISSE UNASSIGNED

Die Pathogenese der SSc bleibt bislang weiterhin nicht gänzlich geklärt. ACR(American College of Rheumatology)/EULAR(European League Against Rheumatism)-Kriterien erlauben eine Diagnose auch früher SSc-Formen. Die Klassifikation in limitierte kutane systemische Sklerose (lcSSc) und diffuse kutane systemische Sklerose (dcSSc) ist von prognostischer und therapeutischer Relevanz. Neue organspezifische Therapiemöglichkeiten der SSc haben zu einer verbesserten Lebensqualität und Prognose geführt.

Autres résumés

Type: Publisher (ger)

Identifiants

DOI: 10.1007/s00105-024-05298-8 PMID: 38366245

pubmed: 38366245

doi: 10.1007/s00105-024-05298-8

pii: 10.1007/s00105-024-05298-8

doi:

Types de publication

English Abstract Journal Article Review

Langues

ger

Sous-ensembles de citation

Informations de copyright

Références

Bergamasco A et al (2019) Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease. Clin Epidemiol 11:257–273

pubmed: 31114386 pmcid: 6497473 doi: 10.2147/CLEP.S191418

Jerjen R et al (2022) Systemic sclerosis in adults. Part I: clinical features and pathogenesis. J Am Acad Dermatol 87(5):937–954

pubmed: 35131402 doi: 10.1016/j.jaad.2021.10.065

Arnett FC et al (2001) Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum 44(6):1359–1362

pubmed: 11407695 doi: 10.1002/1529-0131(200106)44:6<1359::AID-ART228>3.0.CO;2-S

Rosendahl AH, Schonborn K, Krieg T (2022) Pathophysiology of systemic sclerosis (scleroderma). Kaohsiung J Med Sci 38(3):187–195

pubmed: 35234358 doi: 10.1002/kjm2.12505

De Martinis M et al (2016) An overview of environmental risk factors in systemic sclerosis. Expert Rev Clin Immunol 12(4):465–478

pubmed: 26610037 doi: 10.1586/1744666X.2016.1125782

Katsumoto TR, Whitfield ML, Connolly MK (2011) The pathogenesis of systemic sclerosis. Annu Rev Pathol 6:509–537

pubmed: 21090968 doi: 10.1146/annurev-pathol-011110-130312

van den Hoogen F et al (2013) 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 72(11):1747–1755

pubmed: 24092682 doi: 10.1136/annrheumdis-2013-204424

LeRoy EC et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15(2):202–205

pubmed: 3361530

LeRoy EC, Medsger TA Jr. (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28(7):1573–1576

pubmed: 11469464

Sticherling M (2019) Systemic sclerosis—the dermatological perspective. J Dtsch Dermatol Ges 17(7):716–728

pubmed: 31364296

Harvey GR et al (1999) Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis. Clin Exp Immunol 117(2):395–402

pubmed: 10444276 pmcid: 1905338 doi: 10.1046/j.1365-2249.1999.00964.x

Knobler R et al (2017) European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, part 1: localized scleroderma, systemic sclerosis and overlap syndromes. J Eur Acad Dermatol Venereol 31(9):1401–1424

pubmed: 28792092 doi: 10.1111/jdv.14458

Bellando-Randone S, Matucci-Cerinic M (2019) Very early systemic sclerosis. Best Pract Res Clin Rheumatol 33(4):101428

pubmed: 31810547 doi: 10.1016/j.berh.2019.101428

Hunzelmann N et al (2008) The registry of the German network for systemic scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology 47(8):1185–1192

pubmed: 18515867 pmcid: 2468885 doi: 10.1093/rheumatology/ken179

Sticherling M (2019) Systemische sklerodermie – die dermatologische sicht. J Dtsch Dermatol Ges 17(7):716–729

pubmed: 31364296

Devgire V, Hughes M (2019) Raynaud’s phenomenon. Br J Hosp Med 80(11):658–664

doi: 10.12968/hmed.2019.80.11.658

Adigun R, Goyal A, Hariz A (2023) Systemic Sclerosis, in StatPearls. In: Treasure Island (FL) ineligible companies. Disclosure: Amandeep Goyal declares no relevant financial relationships with ineligible companies. Disclosure: Anis Hariz declares no relevant financial relationships with ineligible companies

Vitiello M et al (2012) An update on the treatment of the cutaneous manifestations of systemic sclerosis: the dermatologist’s point of view. J Clin Aesthet Dermatol 5(7):33–43

pubmed: 22798974 pmcid: 3396456

Cruz-Dominguez MP et al (2017) Clinical, biochemical, and radiological characterization of the calcinosis in a cohort of mexican patients with systemic sclerosis. Clin Rheumatol 36(1):111–117

pubmed: 27718018 doi: 10.1007/s10067-016-3412-9

Belz D, Hunzelmann N, Moinzadeh P (2014) Digital ulcers in systemic scleroderma. Hautarzt 65(11):944–948

pubmed: 25336296 doi: 10.1007/s00105-014-3528-2

Hachulla E et al (2007) Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol 34(12):2423–2430

pubmed: 17985402

Amanzi L et al (2010) Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 digital lesions. Rheumatology 49(7):1374–1382

pubmed: 20400463 doi: 10.1093/rheumatology/keq097

Sunderkotter C et al (2009) Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. Br J Dermatol 160(4):835–843

pubmed: 19183180 doi: 10.1111/j.1365-2133.2008.09004.x

Hughes M et al (2021) Digital ulcers in systemic sclerosis. Presse Med 50(1):104064

pubmed: 33548375 doi: 10.1016/j.lpm.2021.104064

Mihai C et al (2016) Digital ulcers predict a worse disease course in patients with systemic sclerosis. Ann Rheum Dis 75(4):681–686

pubmed: 25688073 doi: 10.1136/annrheumdis-2014-205897

Bruni C et al (2015) Digital ulcers as a sentinel sign for early internal organ involvement in very early systemic sclerosis. Rheumatology 54(1):72–76

pubmed: 25065009 doi: 10.1093/rheumatology/keu296

Giuggioli D et al (2012) Scleroderma digital ulcers complicated by infection with fecal pathogens. Arthritis Care Res 64(2):295–297

doi: 10.1002/acr.20673

Sticherling M (2012) Systemic sclerosis-dermatological aspects. Part 1: pathogenesis, epidemiology, clinical findings. J Dtsch Dermatol Ges 10(10):705–718 (quiz 716)

pubmed: 22913330

Odonwodo A, Badri T, Hariz A (2023) Scleroderma, in StatPearls. In: Treasure Island (FL) ineligible companies. Disclosure: Talel Badri declares no relevant financial relationships with ineligible companies. Disclosure: Anis Hariz declares no relevant financial relationships with ineligible companies

Moinzadeh P et al (2023) Impact of systemic sclerosis-associated interstitial lung disease with and without pulmonary hypertension on survival: a large cohort study of the German network for systemic sclerosis. Chest

Lescoat A et al (2023) Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region. Rheumatology 62(6):2178–2188

pubmed: 36222557 doi: 10.1093/rheumatology/keac576

Nihtyanova SI et al (2014) Prediction of pulmonary complications and long term survival in systemic sclerosis. Arthritis Rheumatol

Moinzadeh P et al (2014) Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis

Denton CP, Khanna D (2017) Systemic sclerosis. Lancet 390(10103):1685–1699

pubmed: 28413064 doi: 10.1016/S0140-6736(17)30933-9

Ntusi NA et al (2014) Subclinical myocardial inflammation and diffuse fibrosis are common in systemic sclerosis—a clinical study using myocardial T1-mapping and extracellular volume quantification. J Cardiovasc Magn Reson 16:21

pubmed: 24593856 pmcid: 3996013 doi: 10.1186/1532-429X-16-21

Balaj R, Poanta L, Rednic S (2012) Cardiac involvement in systemic sclerosis. Rom J Intern Med 50(4):269–274

pubmed: 23610974

Poudel DR, Derk CT (2018) Mortality and survival in systemic sclerosis: a review of recent literature. Curr Opin Rheumatol 30(6):588–593

pubmed: 30148801 doi: 10.1097/BOR.0000000000000551

Moinzadeh P et al (2020) Scleroderma renal crisis: risk factors for an increasingly rare organ complication. J Rheumatol 47(2):241–248

pubmed: 30936287 doi: 10.3899/jrheum.180582

Cutolo M et al (2000) Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 27(1):155–160

pubmed: 10648032

Hasseli-Frabel R et al (2022) Nailfold capillaroscopy-principles and clinical application. Z Rheumatol 81(4):313–322

pubmed: 35445832 pmcid: 9022415

Mierau R et al (2011) Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features. Arthritis Res Ther 13(5):R172

pubmed: 22018289 pmcid: 3308107 doi: 10.1186/ar3495

Moinzadeh P et al (2014) Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res Ther 16(1):R53

pubmed: 24524733 pmcid: 3978927 doi: 10.1186/ar4486

Gabrielli A, Avvedimento EV, Krieg T (2009) Scleroderma. N Engl J Med 360(19):1989–2003

pubmed: 19420368 doi: 10.1056/NEJMra0806188

Van Praet JT et al (2011) Histopathological cutaneous alterations in systemic sclerosis: a clinicopathological study. Arthritis Res Ther 13(1):R35

pubmed: 21356083 pmcid: 3241379 doi: 10.1186/ar3267

Hunzelmann N (2018) Current treatment of systemic scleroderma. Hautarzt 69(11):901–907

pubmed: 30143809 doi: 10.1007/s00105-018-4258-7

Hunzelmann N et al (2008) Organ-specific diagnosis in patients with systemic sclerosis: Recommendations of the German Network for Systemic Sclerosis (DNSS). Z Rheumatol 67(4):334–336 (337–40)

pubmed: 18418613 doi: 10.1007/s00393-008-0291-8

Siqueira VS et al (2022) Predictors of progression to systemic sclerosis: analysis of very early diagnosis of systemic sclerosis in a large single-centre cohort. Rheumatology 61(9):3686–3692

pubmed: 35020814 doi: 10.1093/rheumatology/keac006

Hughes M, Herrick AL (2019) Systemic sclerosis. Br J Hosp Med 80(9):530–536

doi: 10.12968/hmed.2019.80.9.530

Kowal-Bielecka O et al (2009) EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 68(5):620–628

pubmed: 19147617 doi: 10.1136/ard.2008.096677

Hughes M et al (2015) Consensus best practice pathway of the UK scleroderma study group: digital vasculopathy in systemic sclerosis. Rheumatology 54(11):2015–2024

pubmed: 26116156 doi: 10.1093/rheumatology/kev201

Kowal-Bielecka O et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76(8):1327–1339

pubmed: 27941129 doi: 10.1136/annrheumdis-2016-209909

Juche A et al (2020) Reality of inpatient vasoactive treatment with prostacyclin derivatives in patients with acral circulation disorders due to systemic sclerosis in Germany. Z Rheumatol 79(10):1057–1066

pubmed: 32040755 pmcid: 7708340 doi: 10.1007/s00393-019-00743-9

Matucci-Cerinic M et al (2011) Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS‑2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 70(1):32–38

pubmed: 20805294 doi: 10.1136/ard.2010.130658

Hughes M, Khanna D, Pauling JD (2020) Drug initiation and escalation strategies of vasodilator therapies for raynaud’s phenomenon: can we treat to target? Rheumatology 59(3):464–466

pubmed: 31670800 doi: 10.1093/rheumatology/kez522

Jerjen R et al (2022) Systemic sclerosis in adults. Part II: management and therapeutics. J Am Acad Dermatol 87(5):957–978

pubmed: 35131401 doi: 10.1016/j.jaad.2021.10.066

Saddic N et al (2009) Surgical debridement of painful fingertip calcinosis cutis in CREST syndrome. Arch Dermatol 145(2):212–213

pubmed: 19221282 doi: 10.1001/archderm.145.2.212-b

Kreuter A et al (2004) Low-dose UVA1 phototherapy in systemic sclerosis: effects on acrosclerosis. J Am Acad Dermatol 50(5):740–747

pubmed: 15097958 doi: 10.1016/j.jaad.2003.08.026

Das SN et al (2005) Placebo controlled trial of methotrexate in systemic sclerosis. Mymensingh Med J 14(1):71–74

pubmed: 15695960

Sullivan KM et al (2018) Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med 378(1):35–47

pubmed: 29298160 pmcid: 5846574 doi: 10.1056/NEJMoa1703327

Blank N et al (2022) Autologous hematopoietic stem cell transplantation improves long-term survival-data from a national registry. Arthritis Res Ther 24(1):258

pubmed: 36424638 pmcid: 9685870 doi: 10.1186/s13075-022-02948-x

Steen VD, Medsger TA Jr. (1998) Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 41(9):1613–1619

pubmed: 9751093 doi: 10.1002/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O

Volkmann ER, McMahan Z (2022) Gastrointestinal involvement in systemic sclerosis: pathogenesis, assessment and treatment. Curr Opin Rheumatol 34(6):328–336

pubmed: 35993874 pmcid: 9547962 doi: 10.1097/BOR.0000000000000899

Distler O et al (2019) Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 380(26):2518–2528

pubmed: 31112379 doi: 10.1056/NEJMoa1903076

Solomon JJ et al (2013) Scleroderma lung disease. Eur Respir Rev 22(127):6–19

pubmed: 23457159 pmcid: 4103193 doi: 10.1183/09059180.00005512